Africa: New Dosing Guidance for Dolutegravir Allows Neonates Born to Mothers with HIV to Access this ARV Drug for the First Time – CROI Research

The PETITE-DTG study evaluated the dosing and safety of dolutegravir (DTG) in neonates born to mothers living with HIV. The study assessed a pediatric dispersible tablet and an oral film, finding the dosing strategy to be safe and effective. The PETITE PLATFORM aims to accelerate neonatal dosing recommendations for ARVs, with the goal of expanding access to the latest advancements in HIV care for newborns. The study showed high levels of acceptability for both DTG formulations, potentially improving HIV prevention and treatment options for neonates.

Full Article